Home » Stocks » OPTN

OptiNose, Inc. (OPTN)

Stock Price: $3.12 USD 0.03 (0.97%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $3.11 -0.01 (-0.22%) May 13, 4:11 PM
Market Cap 164.12M
Revenue (ttm) 54.02M
Net Income (ttm) -96.98M
Shares Out 53.00M
EPS (ttm) -1.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $3.12
Previous Close $3.09
Change ($) 0.03
Change (%) 0.97%
Day's Open 3.07
Day's Range 3.01 - 3.19
Day's Volume 255,923
52-Week Range 2.80 - 10.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

OptiNose (OPTN) delivered earnings and revenue surprises of 5.77% and 4.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Shares of OptiNose (NASDAQ:OPTN) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were up 22.22% year over year to ($0.49), which beat the estimate of ($0....

1 week ago - Benzinga

Company reports first quarter total revenue of $12.0 million

1 week ago - GlobeNewsWire

OptiNose (NASDAQ:OPTN) announces its next round of earnings this Wednesday, May 05. Here is Benzinga's everything-that-matters guide for this Wednesday's Q1 earnings announcement.

1 week ago - Benzinga

Conference Call and Webcast to be held May 5, 2021 at 8:00 a.m. Eastern Time

2 weeks ago - GlobeNewsWire

YARDLEY, Pa., April 27, 2021 /PRNewswire/ -- Optinose, (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced results...

2 weeks ago - PRNewsWire

YARDLEY, Pa., April 12, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that ...

1 month ago - GlobeNewsWire

OptiNose (OPTN) delivered earnings and revenue surprises of -2.22% and -10.41%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of OptiNose (NASDAQ:OPTN) decreased 0.8% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 20.69% over the past year to ($0.46), which were in...

2 months ago - Benzinga

OptiNose (NASDAQ:OPTN) unveils its next round of earnings this Wednesday, March 03. Here is Benzinga's everything-that-matters guide for the earnings announcement.

2 months ago - Benzinga

OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Conference Call and Webcast to be held March 3, 2021 at 8:00 a.m. Eastern Time

2 months ago - GlobeNewsWire

YARDLEY, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Opti N ose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announce...

3 months ago - GlobeNewsWire

YARDLEY, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Opti N ose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announce...

4 months ago - GlobeNewsWire

YARDLEY, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Bo...

5 months ago - GlobeNewsWire

After COVID-19 slowed their commercial launch, OPTN is doing an exceptional job selling Xhance. Q3 2020 revenues grew ~50% from Q2 & consensus FY2021 revenue estimates forecast 100% growth. Professional...

5 months ago - Seeking Alpha

OptiNose (OPTN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

5 months ago - Zacks Investment Research

OptiNose, Inc. (OPTN) CEO Peter Miller on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Preliminary X HANCE Net Revenue G rowth of 78% C ompared to Third Quarter 2019 and 50% C ompared to Second Quarter 2020

6 months ago - GlobeNewsWire

YARDLEY, Pa., Sept. 29, 2020 /PRNewswire/ -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the peer-...

7 months ago - PRNewsWire

YARDLEY, Pa., Sept. 14, 2020 (GLOBE NEWSWIRE) --   Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced ...

7 months ago - GlobeNewsWire

OptiNose has not performed well since its IPO and comes under more pressure, caused by the coronavirus.

8 months ago - Seeking Alpha

Some stock offerings dilute -- but not all.

Other stocks mentioned: NOVA, RMNI
8 months ago - The Motley Fool

Shares of Optinose Inc. OPTN, +2.49% plunged 23% in premarket trading Friday, after the specialty pharmaceuticals company, focused on ear, nose, throat and allergy patients, said its stock offering pric...

8 months ago - Market Watch

YARDLEY, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced the pricin...

8 months ago - GlobeNewsWire

YARDLEY, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced the commen...

9 months ago - GlobeNewsWire

OptiNose, Inc. (OPTN) CEO Peter Miller on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

OptiNose (OPTN) delivered earnings and revenue surprises of -9.80% and -1.04%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

YARDLEY, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced th...

9 months ago - GlobeNewsWire

YARDLEY, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced it...

9 months ago - GlobeNewsWire

YARDLEY, Pa., July 08, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced th...

10 months ago - GlobeNewsWire

OptiNose Inc. (NASDAQ: OPTN) shares popped on Tuesday after the company announced that it is making a move toward fighting COVID-19 with its tech.

10 months ago - 24/7 Wall Street

Company initiates development program using its EDS technology to deliver a nasal “antiseptic” intended to reduce illness and transmission of the COVID-19 virus Company initiates development program usi...

10 months ago - GlobeNewsWire

YARDLEY, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced th...

10 months ago - GlobeNewsWire

YARDLEY, Pa., June 19, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced th...

10 months ago - GlobeNewsWire

OptiNose, Inc. (OPTN) CEO Peter Miller on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

OptiNose, Inc. (OPTN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

1 year ago - Zacks Investment Research

Optinose, Inc. (OPTN) CEO Peter Miller on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

OptiNose (OPTN) delivered earnings and revenue surprises of 13.43% and -11.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

YARDLEY, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the ...

1 year ago - GlobeNewsWire

YARDLEY, Pa., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...

1 year ago - GlobeNewsWire

A secondary offering resets the valuation of the ear, nose, and throat specialist.

1 year ago - The Motley Fool

Optinose, Inc.'s (OPTN) CEO Peter Miller on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Investors are looking for the stocks that have the potential to lift their portfolios to new heights.

Other stocks mentioned: AMRN, CELH, EHTH, GTBIF, HIIQ, ZYNE
1 year ago - InvestorPlace

YARDLEY, Pa., Oct. 04, 2019 (GLOBE NEWSWIRE) --   Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported the...

1 year ago - GlobeNewsWire

YARDLEY, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced t...

1 year ago - GlobeNewsWire

YARDLEY, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- OptiNose , Inc. (Optinose) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists,...

1 year ago - GlobeNewsWire

Company reiterates guidance for XHANCE net revenues for 2019 to be in the range of $29 - $34 million Company reiterates guidance for XHANCE net revenues for 2019 to be in the range of $29 - $34 million

1 year ago - GlobeNewsWire

About OPTN

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase 3b clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also d... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Oct 13, 2017
CEO
Peter Miller
Employees
204
Stock Exchange
NASDAQ
Ticker Symbol
OPTN
Full Company Profile

Financial Performance

In 2020, OptiNose's revenue was $49.12 million, an increase of 41.83% compared to the previous year's $34.63 million. Losses were -$99.79 million, -9.33% less than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for OptiNose stock is "Buy." The 12-month stock price forecast is 14.67, which is an increase of 370.19% from the latest price.

Price Target
$14.67
(370.19% upside)
Analyst Consensus: Buy